Coronary/Structural Heart

United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

– Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences – Separately, total PAH-related patient healthcare costs are 67% higher for selexipag in article published in Drugs – Real World Outcomes SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, […]

VisCardia Announces Its Novel Heart Failure Therapy Receives Breakthrough Device Designation From the FDA

PORTLAND, Ore., April 23, 2020 /PRNewswire/ — VisCardia Inc., a privately held medical device developer, announced today it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its implantable VisONE® system designed for the treatment of moderate to severe heart failure with reduced ejection fraction and preserved ventricular […]

LivaNova Permitted to Modify Cardiopulmonary Products’ Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19

Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for Extracorporeal Membrane Oxygenation (ECMO) therapy greater […]

TDK Ventures Invests in Biomagnetic Medical Imaging Company Genetesis

SAN JOSE, Calif.–(BUSINESS WIRE)–TDK Corporation (TSE:6762) announces that subsidiary TDK Ventures Inc. adds to its growing portfolio of companies with an investment in Genetesis, a world leader in non-invasive biomagnetic imaging. Genetesis is the fifth investment by the TDK corporate venture capital (CVC) fund, and first in digital healthcare, since its July 2019 […]

KARL STORZ and Saphena Medical to Provide Integrated Solutions for EVH Procedures

Innovative Products Promote Effective Clinical Care and Reduce Overall Costs EL SEGUNDO, Calif.–(BUSINESS WIRE)–KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology, is pleased to announce a new partnership with Saphena Medical to provide advanced instruments for endoscopic vessel harvesting (EVH). EVH is a revolutionary procedure that enables […]

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids LAVAL, Québec, April 20, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 […]

ImpediMed Releases Most Comprehensive Software Package for SOZO® Digital Health Platform

Bioimpedance Spectroscopy Technology Used by Hospitals and Large Oncology Groups as Part of Lymphedema Prevention Program Adds Heart Failure and Renal Disease Capabilities CARLSBAD, Calif., April 20, 2020 /PRNewswire/ — ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today […]

Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners to Continue Clinical Trials With Its Leaflex™ Aortic Valve Technology

REHOVOT, Israel, April 20, 2020 /PRNewswire/ — Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million round of financing, led by Sofinnova Partners, a leading European life sciences venture capital firm, and joined by Professor Jacques Séguin, Chairman of the […]

VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/ SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the acceleration of its pipeline clinical development, of plant-derived active substances, in new indications: cardiovascular and hepatic steatosis risk. Building […]

CareDx Introduces AlloCell: Cell Therapy Surveillance

CareDx Announces Collaborations to Develop Cellular Therapy Diagnostics SOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today a biopharma research partnership […]